Over the last decade, more than 50 drug candidates targeting Aβ or tau protein have successfully passed phase II clinical trials, but none has passed a phase III clinical trial, as the precise molecular mechanisms of AD are still not fully understood [36]. The gene discussed is MAPT; the disease is Alzheimer disease.